SG11201805506YA - Modulators of 5'-nucleotidase, ecto and the use thereof - Google Patents
Modulators of 5'-nucleotidase, ecto and the use thereofInfo
- Publication number
- SG11201805506YA SG11201805506YA SG11201805506YA SG11201805506YA SG11201805506YA SG 11201805506Y A SG11201805506Y A SG 11201805506YA SG 11201805506Y A SG11201805506Y A SG 11201805506YA SG 11201805506Y A SG11201805506Y A SG 11201805506YA SG 11201805506Y A SG11201805506Y A SG 11201805506YA
- Authority
- SG
- Singapore
- Prior art keywords
- ecto
- international
- avenue
- nucleotidase
- street
- Prior art date
Links
- 102000004008 5'-Nucleotidase Human genes 0.000 title abstract 4
- 108010043671 prostatic acid phosphatase Proteins 0.000 title abstract 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 2
- 229960005305 adenosine Drugs 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102100022464 5'-nucleotidase Human genes 0.000 abstract 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 102000009609 Pyrophosphatases Human genes 0.000 abstract 1
- 108010009413 Pyrophosphatases Proteins 0.000 abstract 1
- 240000001749 Quercus lobata Species 0.000 abstract 1
- 235000013400 Quercus lobata Nutrition 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 235000011178 triphosphate Nutrition 0.000 abstract 1
- 239000001226 triphosphate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization IIIMI41101110101011111 HO 1111101110111 0101111110011111110111110 ill OEN International Bureau ... ..... ..Yi j (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/120508 Al 13 July 2017 (13.07.2017) WI P0 I P CT (51) International Patent Classification: KALISIAK, Jaroslaw; 1031 Crestview Drive, Apt. 104, A61K 31/70 (2006.01) C07H 19/16 (2006.01) Mountain View, CA 94040 (US). LAWSON, Kenneth V.; A61K 31/7052 (2006.01) C07H 19/20 (2006.01) 1221 Masonic Avenue, #10, San Francisco, CA 94117 A61K 31/7076 (2006.01) CO7H 19/207 (2006.01) (US). LELETI, Manmohan Reddy; 7269 Ventana Drive, (21) International Application Number: West San Jose, CA 95129 (US). LINDSEY, Erick, Allen; PCT/US2017/012587 44 Burnham Place, Fremont, CA 94539 (US). MILES, Dillon Harding; 2320 Haste Street, #14, Berkeley, CA (22) International Filing Date: 94074 (US). NEWCOMB, Eric; 825 Live Oak Avenue, 6 January 2017 (06.01.2017) Unit K, Menlo Park, CA 94025 (US). POWERS, Jay (25) Filing Language: English Patrick; 745 Rockaway Beach Avenue, Pacifica, CA 94044 (US). ROSEN, Brandon Reid; 2321 Hacienda (26) Publication Language: English Street, San Mateo, CA 94403 (US). SHARIF, Ehesan Ui; 1793 Santa Cruz Avenue, Menlo Park, CA 94025 (US). (30) Priority Data: 62/276,564 8 January 2016 (08.01.2016) US (74) Agents: KEZER, William B. et al.; Mintz Levin Cohn 62/324,077 18 April 2016 (18.04.2016) US Ferris Glovsky And Popeo, P.C., One Financial Center, Boston, MA 02111 (US). (71) Applicant: ARCUS BIOSCIENCES, INC. [US/US]; 3928 Point Eden Way, Hayward, CA 94545 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (72) Inventors: DEBIEN, Laurent, Pierre Paul; 461 Andover AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, Street, San Francisco, CA 94110 (US). JAEN, Juan, Car- BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, los; 154 Los Robles Drive, Burlingame, CA 94010 (US). [Continued on next page] = (54) Title: MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF (57) : Compounds that modu- FIG. = 1 late the conversion of AMP to aden- osine by 5'- nucleotidase, ecto, and = — compositions containing the com- pounds and methods for synthesizing the compounds, are described herein. = The use of such compounds and com- positions for the treatment and/or pre- diverse diseases, = Extracellular ....N vention of a array of disorders and conditions, including cancer- and immune-related disorders, . ATP ADP AMP Adenosine that are mediated by 5'-nucleotidase, = 2 is also 0 ilo. _3_ 0. ecto provided. = 0 0 31 © 0 0 Outer Membrane = = Pannexin-'71 -- _ ‘...../ P2X ATP P2Y & ` \--=/ AR --/ \S Inner Membrane 1-1 Intracellular Ot 0 in 0 1. Ecto-nucleotide pyrophosphatase/ phosphodiesterase (E-NPP) 2. Ecto-nucleoside triphosphate diphosphydrolase (E-NTDPase) 3. Ecto-5'-nuclrotidase/CD73 ei ,-1 IN ,-1 © ei O WO 2017/120508 Al MIDEDIMOMOIDEIROIDEOMMMIIMEMOMEHMIE DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, RU, KZ, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, LY, NA, TJ, TM), European (AL, AT, BE, BG, CH, CY, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, CZ, IT, RS, SE, DE, LT, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, ZA, ZM, ZW. SV, VC, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). GA, Published: (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, with international search report (Art. 21(3))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276564P | 2016-01-08 | 2016-01-08 | |
| US201662324077P | 2016-04-18 | 2016-04-18 | |
| PCT/US2017/012587 WO2017120508A1 (en) | 2016-01-08 | 2017-01-06 | Modulators of 5'-nucleotidase, ecto and the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805506YA true SG11201805506YA (en) | 2018-07-30 |
Family
ID=59274491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805506YA SG11201805506YA (en) | 2016-01-08 | 2017-01-06 | Modulators of 5'-nucleotidase, ecto and the use thereof |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US10239912B2 (en) |
| EP (2) | EP4306525A3 (en) |
| JP (3) | JP6920344B2 (en) |
| KR (1) | KR20180100638A (en) |
| CN (2) | CN108697719B (en) |
| AU (2) | AU2017206061B2 (en) |
| BR (1) | BR112018013827B1 (en) |
| CA (2) | CA3009196C (en) |
| CL (1) | CL2018001845A1 (en) |
| DK (1) | DK3399984T3 (en) |
| EA (1) | EA038565B1 (en) |
| ES (1) | ES2963759T3 (en) |
| FI (1) | FI3399984T3 (en) |
| HR (1) | HRP20231155T1 (en) |
| HU (1) | HUE063388T2 (en) |
| IL (1) | IL260260B2 (en) |
| LT (1) | LT3399984T (en) |
| MX (2) | MX2018008350A (en) |
| PH (1) | PH12018501361A1 (en) |
| PL (1) | PL3399984T3 (en) |
| PT (1) | PT3399984T (en) |
| SA (1) | SA518391985B1 (en) |
| SG (1) | SG11201805506YA (en) |
| SI (1) | SI3399984T1 (en) |
| TW (2) | TW202227095A (en) |
| UA (1) | UA124529C2 (en) |
| WO (1) | WO2017120508A1 (en) |
| ZA (2) | ZA201804350B (en) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3399984T3 (en) | 2016-01-08 | 2024-02-19 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
| US10472364B2 (en) | 2016-09-09 | 2019-11-12 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| TWI786072B (en) * | 2016-11-18 | 2022-12-11 | 美商阿克思生物科學有限公司 | Inhibitors of cd73-mediated immunosuppression |
| CR20190268A (en) | 2016-12-08 | 2019-07-11 | Hoffmann La Roche | New isoxazolyl ether derivatives as gaba a alpha5 pam |
| NZ754171A (en) * | 2016-12-22 | 2022-12-23 | Calithera Biosciences Inc | Ectonucleotidase inhibitors and methods of use thereof |
| KR102584011B1 (en) | 2017-03-16 | 2023-09-27 | 이나뜨 파르마 에스.에이. | Compositions and methods for treating cancer |
| US11129841B2 (en) | 2017-05-10 | 2021-09-28 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| KR20200060471A (en) | 2017-10-06 | 2020-05-29 | 이나뜨 파르마 | Restoration of T cell activity through the CD39 / CD73 axis |
| WO2019090111A1 (en) * | 2017-11-03 | 2019-05-09 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| CN111094317B (en) * | 2017-12-29 | 2023-03-31 | 上海和誉生物医药科技有限公司 | Phosphonic acid derivative with CD73 inhibitory activity, and preparation method and application thereof |
| TWI702954B (en) | 2018-03-01 | 2020-09-01 | 美商美國禮來大藥廠 | Cd73 inhibitors |
| CA3092585A1 (en) * | 2018-03-09 | 2019-09-12 | Arcus Biosciences, Inc. | Parenterally administered immune enhancing drugs |
| SG11202010790XA (en) | 2018-04-30 | 2020-11-27 | Oric Pharmaceuticals Inc | Cd73 inhibitors |
| JP7500442B2 (en) | 2018-06-18 | 2024-06-17 | イナート・ファルマ・ソシエテ・アノニム | Compositions and methods for treating cancer |
| US20210169911A1 (en) * | 2018-08-17 | 2021-06-10 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Purine and pyrimidine nucleotides as ecto-5'-nucleotidase inhibitors |
| WO2020047082A1 (en) | 2018-08-28 | 2020-03-05 | Eternity Bioscience Inc. | Cd73 inhibitors and therapeutic uses thereof |
| CN110885352B (en) * | 2018-09-11 | 2023-02-24 | 润佳（苏州）医药科技有限公司 | CD73 inhibitor and pharmaceutical application thereof |
| EP3849992A4 (en) | 2018-09-11 | 2022-06-29 | Risen (Suzhou) Pharma Tech Co., Ltd. | Cd73 inhibitors and pharmaceutical uses thereof |
| US11530234B2 (en) | 2018-09-11 | 2022-12-20 | Risen (Suzhou) Pharma Tech Co., Ltd. | CD73 inhibitors and pharmaceutical uses thereof |
| WO2020123772A1 (en) * | 2018-12-13 | 2020-06-18 | Arcus Biosciences, Inc. | Solid forms of a cd73 inhibitor and the use thereof |
| US20200345725A1 (en) | 2019-01-11 | 2020-11-05 | Omeros Corporation | Methods and Compositions for Treating Cancer |
| CN112955444B (en) * | 2019-01-22 | 2023-12-12 | 江苏恒瑞医药股份有限公司 | Novel small molecule CD73 inhibitor, preparation method thereof and application thereof in medicine |
| CA3133078A1 (en) * | 2019-03-12 | 2020-09-17 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| AU2020256098A1 (en) * | 2019-03-29 | 2021-10-28 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| WO2020205538A1 (en) * | 2019-03-29 | 2020-10-08 | Eternity Bioscience Inc. | Cd73 inhibitors and therapeutic uses thereof |
| EP3952874A4 (en) * | 2019-04-05 | 2022-12-28 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| WO2020210938A1 (en) * | 2019-04-15 | 2020-10-22 | Bioardis Llc | Quinazoline derivatives as cd73 inhibitors |
| WO2020210970A1 (en) * | 2019-04-16 | 2020-10-22 | Bioardis Llc | Imidazotriazine derivatives as cd73 inhibitors |
| TWI821559B (en) * | 2019-04-28 | 2023-11-11 | 大陸商上海和譽生物醫藥科技有限公司 | A CD73 inhibitor, its preparation method and application |
| WO2021040356A1 (en) * | 2019-08-23 | 2021-03-04 | Kainos Medicine, Inc. | C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition |
| BR112022001365A2 (en) * | 2019-08-29 | 2022-06-07 | Lilly Co Eli | Crystalline forms of a cd73 inhibitor |
| CN114929721B (en) * | 2019-10-30 | 2023-07-18 | 欧瑞克制药公司 | CD73 inhibitors |
| TW202131932A (en) * | 2019-11-05 | 2021-09-01 | 美商博奥阿迪斯有限公司 | Compounds as cd73 inhibitors |
| US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
| MX2022011534A (en) | 2020-03-19 | 2022-10-13 | Arcus Biosciences Inc | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha. |
| PE20231078A1 (en) | 2020-06-02 | 2023-07-17 | Arcus Biosciences Inc | ANTI-TIGIT ANTIBODIES |
| WO2021247188A1 (en) | 2020-06-05 | 2021-12-09 | Bristol-Myers Squibb Company | Cd73 antagonist potency assay and methods of use thereof |
| JP2023530456A (en) * | 2020-06-17 | 2023-07-18 | アーカス バイオサイエンシズ インコーポレイティド | Crystal forms of CD73 inhibitors and uses thereof |
| CN115702150A (en) * | 2020-07-07 | 2023-02-14 | 贝达药业股份有限公司 | CD73 inhibitor and application thereof in medicine |
| US20230321100A1 (en) * | 2020-09-08 | 2023-10-12 | Betta Pharmaceuticals Co., Ltd | Cd73 inhibitor and application thereof in medicine |
| CN114437038A (en) * | 2020-11-05 | 2022-05-06 | 武汉人福创新药物研发中心有限公司 | Pyridazine alkyne compound and application thereof |
| JP2023548204A (en) * | 2020-11-05 | 2023-11-15 | 武漢人福創新薬物研発中心有限公司 | CD73 inhibitors and their applications |
| CN116546990A (en) * | 2020-11-25 | 2023-08-04 | 润佳（苏州）医药科技有限公司 | CD73 inhibitor and pharmaceutical application thereof |
| CN114539340B (en) * | 2020-11-25 | 2024-06-07 | 润佳（苏州）医药科技有限公司 | CD73 inhibitor and pharmaceutical application thereof |
| AU2021413448A1 (en) * | 2020-12-29 | 2023-07-20 | Zhejiang Vimgreen Pharmaceuticals, Ltd | Adenosine a3 receptor agonists, preparation methods and uses thereof |
| WO2022237747A1 (en) | 2021-05-11 | 2022-11-17 | 四川海思科制药有限公司 | Small molecular cd73 antagonist and use thereof |
| WO2022246179A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| JP2024521706A (en) | 2021-05-21 | 2024-06-04 | アーカス バイオサイエンシーズ，インコーポレーテッド | AXL Compound |
| WO2023061319A1 (en) * | 2021-10-11 | 2023-04-20 | 南京明德新药研发有限公司 | Tricyclic heterocyclic derivative |
| WO2023076392A1 (en) * | 2021-10-26 | 2023-05-04 | Southern Research Institute | Development of novel clofarabine analogs for cancer therapy |
| US20230159466A1 (en) | 2021-10-29 | 2023-05-25 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202409083A (en) | 2022-05-02 | 2024-03-01 | 美商阿克思生物科學有限公司 | Anti-tigit antibodies and uses of the same |
| WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024059142A1 (en) | 2022-09-14 | 2024-03-21 | Arcus Biosciences, Inc. | Dispersions of etrumadenant |
| WO2024076872A1 (en) * | 2022-10-03 | 2024-04-11 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| WO2024076873A1 (en) * | 2022-10-03 | 2024-04-11 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| WO2024086718A1 (en) | 2022-10-20 | 2024-04-25 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5569650A (en) * | 1993-06-11 | 1996-10-29 | Sloan-Kettering Institute For Cancer Research | C-nucleoside isosters of analogs thereof and pharmaceutical compositions |
| CN1113888C (en) * | 1996-10-09 | 2003-07-09 | 法玛塞特有限公司 | Tetraphosphonate bicyclic trisanhydrides |
| EP1366055A2 (en) | 2000-12-15 | 2003-12-03 | Pharmasset Limited | Antiviral agents for treatment of flaviviridae infections |
| WO2012032513A1 (en) * | 2010-09-07 | 2012-03-15 | Bar-Ilan University | Boranophosphate derivatives for the treatment of osteoarthritis |
| US9090697B2 (en) | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
| FR3011240A1 (en) * | 2013-10-01 | 2015-04-03 | Centre Nat Rech Scient | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF |
| KR102248804B1 (en) | 2014-03-12 | 2021-05-11 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| MA39986A (en) | 2014-04-25 | 2017-03-01 | Vitae Pharmaceuticals Inc | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| MX2018001871A (en) | 2015-08-17 | 2018-05-28 | Lupin Ltd | Heteroaryl derivatives as parp inhibitors. |
| UY37062A (en) | 2016-01-08 | 2017-08-31 | Syngenta Participations Ag | DERIVATIVES OF ARYL OXADIAZOL FUNGICIDAS |
| EP3808346B1 (en) | 2016-01-08 | 2023-07-19 | Celgene Corporation | Antiproliferative compounds for use in the treatment of leukemia |
| PL3399984T3 (en) | 2016-01-08 | 2024-02-19 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
| CA3092585A1 (en) | 2018-03-09 | 2019-09-12 | Arcus Biosciences, Inc. | Parenterally administered immune enhancing drugs |
| WO2020123772A1 (en) | 2018-12-13 | 2020-06-18 | Arcus Biosciences, Inc. | Solid forms of a cd73 inhibitor and the use thereof |
| JP2023530456A (en) | 2020-06-17 | 2023-07-18 | アーカス バイオサイエンシズ インコーポレイティド | Crystal forms of CD73 inhibitors and uses thereof |
-
2017
- 2017-01-06 PL PL17736459.3T patent/PL3399984T3/en unknown
- 2017-01-06 IL IL260260A patent/IL260260B2/en unknown
- 2017-01-06 AU AU2017206061A patent/AU2017206061B2/en active Active
- 2017-01-06 FI FIEP17736459.3T patent/FI3399984T3/en active
- 2017-01-06 PT PT177364593T patent/PT3399984T/en unknown
- 2017-01-06 CA CA3009196A patent/CA3009196C/en active Active
- 2017-01-06 TW TW110136486A patent/TW202227095A/en unknown
- 2017-01-06 CN CN201780006172.1A patent/CN108697719B/en active Active
- 2017-01-06 CN CN202210014893.XA patent/CN114395005A/en active Pending
- 2017-01-06 JP JP2018554643A patent/JP6920344B2/en active Active
- 2017-01-06 BR BR112018013827-4A patent/BR112018013827B1/en active IP Right Grant
- 2017-01-06 CA CA3151595A patent/CA3151595A1/en active Pending
- 2017-01-06 US US15/400,748 patent/US10239912B2/en active Active
- 2017-01-06 EP EP23194905.8A patent/EP4306525A3/en active Pending
- 2017-01-06 SI SI201731439T patent/SI3399984T1/en unknown
- 2017-01-06 KR KR1020187022597A patent/KR20180100638A/en not_active Application Discontinuation
- 2017-01-06 LT LTEPPCT/US2017/012587T patent/LT3399984T/en unknown
- 2017-01-06 DK DK17736459.3T patent/DK3399984T3/en active
- 2017-01-06 ES ES17736459T patent/ES2963759T3/en active Active
- 2017-01-06 MX MX2018008350A patent/MX2018008350A/en unknown
- 2017-01-06 SG SG11201805506YA patent/SG11201805506YA/en unknown
- 2017-01-06 UA UAA201808490A patent/UA124529C2/en unknown
- 2017-01-06 EA EA201891583A patent/EA038565B1/en unknown
- 2017-01-06 HU HUE17736459A patent/HUE063388T2/en unknown
- 2017-01-06 HR HRP20231155TT patent/HRP20231155T1/en unknown
- 2017-01-06 WO PCT/US2017/012587 patent/WO2017120508A1/en active Application Filing
- 2017-01-06 EP EP17736459.3A patent/EP3399984B1/en active Active
- 2017-01-06 TW TW106100542A patent/TWI744274B/en active
-
2018
- 2018-06-25 PH PH12018501361A patent/PH12018501361A1/en unknown
- 2018-06-28 ZA ZA2018/04350A patent/ZA201804350B/en unknown
- 2018-07-05 MX MX2022006322A patent/MX2022006322A/en unknown
- 2018-07-05 CL CL2018001845A patent/CL2018001845A1/en unknown
- 2018-07-05 SA SA518391985A patent/SA518391985B1/en unknown
-
2019
- 2019-02-12 US US16/273,843 patent/US10981944B2/en active Active
-
2020
- 2020-09-01 US US17/009,590 patent/US11001603B2/en active Active
-
2021
- 2021-03-19 US US17/206,896 patent/US11667662B2/en active Active
- 2021-07-26 JP JP2021121236A patent/JP7322104B2/en active Active
-
2022
- 2022-08-24 ZA ZA2022/09472A patent/ZA202209472B/en unknown
-
2023
- 2023-03-02 AU AU2023201288A patent/AU2023201288A1/en active Pending
- 2023-07-26 JP JP2023121750A patent/JP2023129628A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805506YA (en) | Modulators of 5'-nucleotidase, ecto and the use thereof | |
| SG11201905812WA (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| SG11201903674YA (en) | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof | |
| SG11201900561XA (en) | Chemokine receptor modulators and uses thereof | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201808821WA (en) | Agonistic antibodies that bind human cd40 and uses thereof | |
| SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
| SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201806650VA (en) | Systems and methods for providing a personal distributed ledger | |
| SG11201809688RA (en) | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | |
| SG11201809336QA (en) | Anti-pd-l1 antibodies | |
| SG11201805136TA (en) | Group b adenovirus encoding an anti-tcr-complex antibody or fragment | |
| SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
| SG11201807770RA (en) | Sequence arrangements and sequences for neoepitope presentation | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201900228YA (en) | Administration and dosage of diaminophenothiazines | |
| SG11201804997XA (en) | Process for preparing non-cariogenic, sustained energy release juice | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201806853VA (en) | Abstracted graphs from social relationship graph | |
| SG11201804856VA (en) | C-terminal lysine conjugated immunoglobulins |